Abstract
High levels of cell-free haemoglobin (Hb) may occur in plasma as a consequence of e.g., pathological haemolysis or blood transfusion. These Hb molecules can be removed from blood circulation by forming a complex with the acute-phase protein haptoglobin (Hp) and thereby can also the intrinsic toxicity of free Hb be limited. In this study it is shown that ferric HbA, HbF, HbE and HbS, respectively, all bind firmly to Hp at 25 °C. By using isothermal titration calorimetry (ITC), it is demonstrated that ferric HbF has higher affinity to Hp (Ka = 2.79 ± 0.29 ×109 M−1) compared with HbA and HbS (1.91 ± 0.24 ×109 M−1) and 1.41 ± 0.34 ×109 M−1 for HbA and HbS, respectively. In addition, the affinity constant for HbE is slightly lower than the other haemoglobins (0.47 ± 0.40 ×109 M−1). Since Hp shows a general and high affinity to all Hb variants tested, it can be concluded that Hp may be useful as a therapeutic agent for several different haemolytic conditions by intravenous injection.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Reeder BJ, Svistunenko DA, Cooper CE et al (2004) The radical and redox chemistry of myoglobin and hemoglobin: from in vitro studies to human pathology. Antioxid Redox Signal 6:954–966
Olsson MG, Allhorn M, Bulow L et al (2012) Pathological conditions involving extracellular hemoglobin: molecular mechanisms, clinical significance, and novel therapeutic opportunities for α(1)-microglobulin. Antioxid Redox Signal 17:813–846
Kato GJ, Hebbel RP, Steinberg MH et al (2009) Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 84:618–625
Rees DC, Williams TN, Gladwin MT (2010) Sickle-cell disease. Lancet 376:2018–2031
Kassim AA, DeBaun MR (2013) Sickle cell disease, vasculopathy, and therapeutics. Annu Rev Med 64:451–466
El-Husseini A, Sabry A (2010) Fatal hyperhemolytic delayed transfusion reaction in sickle cell disease: a case report and literature review. Am J Emerg Med 28:1062.e5–1062.e8
Akinsheye I, Alsultan A, Solovieff N et al (2011) Fetal hemoglobin in sickle cell anemia. Blood 118:19–27
McGann PT, Nero AC, Ware RE (2013) Current management of sickle cell anemia. Cold Spring Harb Perspect Med 3:a011817
Musallam KM, Taher AT, Cappellini MD et al (2013) Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood 121:2199–2212
Kristiansen M, Graversen JH, Jacobsen C et al (2001) Identification of the haemoglobin scavenger receptor. Nature 409:198–201
Baek JH, D'Agnillo F, Vallelian F et al (2012) Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in Guinea pigs by haptoglobin therapy. J Clin Invest 122:1444–1458
Cooper CE, Schaer DJ, Buehler PW et al (2012) Haptoglobin binding stabilizes hemoglobin Ferryl iron and the globin radical on tyrosine β145. Antioxid Redox Signal 18:2264–2273
Alayash AI, Andersen CBF, Moestrup SK et al (2013) Haptoglobin: the hemoglobin detoxifier in plasma. Trends Biotechnol 31:2–3
Ratanasopa K, Chakane S, Ilyas M et al (2013) Trapping of human hemoglobin by Haptoglobin: molecular mechanisms and clinical applications. Antioxid Redox Signal 18:2364–2374
Reeder BJ, Grey M, Silaghi-Dumitrescu RL et al (2008) Tyrosine residues as redox cofactors in human hemoglobin: Implications for engineering nontoxic blood substitutes. J Biol Chem 283:30780–30787
Acknowledgments
This study was supported by grants from the Swedish Research Foundation (VR) and the Swedish Foundation for Strategic Research (SSF).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this paper
Cite this paper
Ratanasopa, K., Bulow, L. (2022). Calorimetric Characterisation of the Binding Reaction Between Human Ferric Haemoglobins and Haptoglobin to Develop a Drug for Removal of Cell-Free Haemoglobin. In: Scholkmann, F., LaManna, J., Wolf, U. (eds) Oxygen Transport to Tissue XLIII. Advances in Experimental Medicine and Biology, vol 1395. Springer, Cham. https://doi.org/10.1007/978-3-031-14190-4_55
Download citation
DOI: https://doi.org/10.1007/978-3-031-14190-4_55
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-14189-8
Online ISBN: 978-3-031-14190-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)